Anatomic Stage IA Breast Cancer AJCC v8 research hub

T-DM1 and Tucatinib Compared With T-DM1 Alone in Preventing Relapses in People With High Risk HER2-Positive Breast Cancer, the CompassHER2 RD Trial

This study looks at two medicines, T-DM1 and tucatinib, to see if combining them is better than T-DM1 alone at stopping high-risk HER2-positive breast cancer from coming back. It focuses on people who still have some cancer cells after their first treatment.